This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brandt, M. E.
Right arrow Articles by Warnock, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brandt, M. E.
Right arrow Articles by Warnock, D. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2001, p. 3065-3069, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3065-3069.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996 to 1998

Mary E. Brandt,1,* Michael A. Pfaller,2 Rana A. Hajjeh,1 Richard J. Hamill,3 Peter G. Pappas,4 Arthur L. Reingold,5 David Rimland,6 and David W. Warnock1,dagger for the Cryptococcal Disease Active Surveillance Group

Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention,1 and Veterans Administration Medical Center and Emory University School of Medicine,6 Atlanta, Georgia; Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa2; Veterans Administration Medical Center and Baylor College of Medicine, Houston, Texas3; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama4; and School of Public Health, University of California at Berkeley, Berkeley, California5

Received 7 May 2001/Returned for modification 14 July 2001/Accepted 3 August 2001

The antifungal drug susceptibilities of two collections of Cryptococcus neoformans isolates obtained through active laboratory-based surveillance from 1992 to 1994 (368 isolates) and 1996 to 1998 (364 isolates) were determined. The MICs of fluconazole, itraconazole, and flucytosine were determined by the National Committee for Clinical Laboratory Standards broth microdilution method; amphotericin B MICs were determined by the E-test. Our results showed that the MIC ranges, the MICs at which 50% of isolates are inhibited (MIC50s), and the MIC90s of these four antifungal agents did not change from 1992 to 1998. In addition, very small numbers of isolates showed elevated MICs suggestive of in vitro resistance. The MICs of amphotericin B were elevated (>= 2 µg/ml) for 2 isolates, and the MICs of flucytosine were elevated (>= 32 µg/ml) for 14 isolates. Among the azoles, the fluconazole MIC was elevated (>= 64 µg/ml) for 8 isolates and the itraconazole MIC (>= 1 µg/ml) was elevated for 45 isolates. Analysis of 172 serial isolates from 71 patients showed little change in the fluconazole MIC over time. For isolates from 58 patients (82% of serial cases) there was either no change or a twofold change in the fluconazole MIC. In contrast, for isolates from seven patients (12% of serial cases) the increase in the MIC was at least fourfold. For isolates from another patient there was a 32-fold decrease in the fluconazole MIC over a 1-month period. We conclude that in vitro resistance to antifungal agents remains uncommon in C. neoformans and has not significantly changed with time during the past decade.

* Corresponding author. Mailing address: Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd., N.E., Mailstop G-11, Atlanta, GA 30333. Phone: (404) 639-0281. Fax: (404) 639-3546. E-mail: Mbrandt{at}cdc.gov.

dagger Study group members are listed in the appendix.

Antimicrobial Agents and Chemotherapy, November 2001, p. 3065-3069, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3065-3069.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Sionov, E., Chang, Y. C., Garraffo, H. M., Kwon-Chung, K. J. (2009). Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence. Antimicrob. Agents Chemother. 53: 2804-2815 [Abstract] [Full Text]  
  • Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., Monk, B. C. (2009). Efflux-Mediated Antifungal Drug Resistance. Clin. Microbiol. Rev. 22: 291-321 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., Rennison, C., Zaidi, M., the Global Antifungal Surveillance Group, (2009). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. J. Clin. Microbiol. 47: 117-123 [Abstract] [Full Text]  
  • Illnait-Zaragozi, M.-T., Martinez, G. F., Curfs-Breuker, I., Fernandez, C. M., Boekhout, T., Meis, J. F. (2008). In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba. Antimicrob. Agents Chemother. 52: 1580-1582 [Abstract] [Full Text]  
  • Khan, Z. U., Randhawa, H. S., Kowshik, T., Chowdhary, A., Chandy, R. (2007). Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother 60: 312-316 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F., Gould, I. M., Fu, W., Colombo, A. L., Rodriguez-Noriega, E., and the Global Antifungal Surveillance Group, (2007). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. J. Clin. Microbiol. 45: 1735-1745 [Abstract] [Full Text]  
  • Schwarz, P., Janbon, G., Dromer, F., Lortholary, O., Dannaoui, E. (2007). Combination of Amphotericin B with Flucytosine Is Active In Vitro against Flucytosine-Resistant Isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 51: 383-385 [Abstract] [Full Text]  
  • Dias, A. L. T., Matsumoto, F. E., Melhem, M. S. C., da Silva, E. G., Auler, M. E., de Siqueira, A. M., Paula, C. R. (2006). Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates.. J Med Microbiol 55: 1693-1699 [Abstract] [Full Text]  
  • Jain, N., Li, L., McFadden, D. C., Banarjee, U., Wang, X., Cook, E., Fries, B. C. (2006). Phenotypic Switching in a Cryptococcus neoformans Variety gattii Strain Is Associated with Changes in Virulence and Promotes Dissemination to the Central Nervous System. Infect. Immun. 74: 896-903 [Abstract] [Full Text]  
  • Sanguinetti, M., Posteraro, B., La Sorda, M., Torelli, R., Fiori, B., Santangelo, R., Delogu, G., Fadda, G. (2006). Role of AFR1, an ABC Transporter-Encoding Gene, in the In Vivo Response to Fluconazole and Virulence of Cryptococcus neoformans. Infect. Immun. 74: 1352-1359 [Abstract] [Full Text]  
  • Guerrero, A., Jain, N., Goldman, D. L., Fries, B. C. (2006). Phenotypic switching in Cryptococcus neoformans. Microbiology 152: 3-9 [Abstract] [Full Text]  
  • Schwarz, P., Dromer, F., Lortholary, O., Dannaoui, E. (2006). Efficacy of Amphotericin B in Combination with Flucytosine against Flucytosine-Susceptible or Flucytosine-Resistant Isolates of Cryptococcus neoformans during Disseminated Murine Cryptococcosis. Antimicrob. Agents Chemother. 50: 113-120 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E., Gibbs, D. L., the Global Antifungal Surveillance Group, (2005). Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing. J. Clin. Microbiol. 43: 5848-5859 [Abstract] [Full Text]  
  • Perkins, A., Gomez-Lopez, A., Mellado, E., Rodriguez-Tudela, J. L., Cuenca-Estrella, M. (2005). Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 56: 1144-1147 [Abstract] [Full Text]  
  • Jain, N., Wickes, B. L., Keller, S. M., Fu, J., Casadevall, A., Jain, P., Ragan, M. A., Banerjee, U., Fries, B. C. (2005). Molecular Epidemiology of Clinical Cryptococcus neoformans Strains from India. J. Clin. Microbiol. 43: 5733-5742 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Messer, S. A., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2005). Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 43: 5208-5213 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Doern, G. V., Diekema, D. J. (2005). Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43: 2163-2167 [Abstract] [Full Text]  
  • Fries, B. C., Cook, E., Wang, X., Casadevall, A. (2005). Effects of Antifungal Interventions on the Outcome of Experimental Infections with Phenotypic Switch Variants of Cryptococcus neoformans. Antimicrob. Agents Chemother. 49: 350-357 [Abstract] [Full Text]  
  • Sar, B., Monchy, D., Vann, M., Keo, C., Sarthou, J. L., Buisson, Y. (2004). Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 54: 563-565 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2004). Evaluation of the NCCLS M44-P Disk Diffusion Method for Determining Susceptibilities of 276 Clinical Isolates of Cryptococcus neoformans to Fluconazole. J. Clin. Microbiol. 42: 380-383 [Abstract] [Full Text]  
  • Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A. K., Boyken, L., Hollis, R. J., Furuta, I., Jones, R. N. (2003). Characterization of Heteroresistance to Fluconazole among Clinical Isolates of Cryptococcus neoformans. J. Clin. Microbiol. 41: 267-272 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N. (2002). Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46: 1032-1037 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»